Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionQuadrant Capital Group Llc
Latest Disclosed Ownership7,689 shares
Latest Disclosed Value $ 1,012,949
Quadrant Capital Group Llc reports 7.12% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 13, 2026 - Quadrant Capital Group Llc filed a 13F-HR/A form disclosing ownership of 7,689 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $1,012,949 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 8,278 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -7.12% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 7,689 -589 -7.12 1,013 -13.80 0.0303
2026-05-11 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,689 -589 49 0.0369
2026-02-12 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,278 20 0.24 1,174 1.29 0.0355
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,258 636 8.34 1,159 20.98 0.0377
2025-08-13 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,622 -359 -4.50 958 8.62 0.0345
2025-05-13 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,981 5,692 248.67 883 182.69 0.0328
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,289 -23 -0.99 312 17.29 0.0215
2024-11-12 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,312 -46 -1.95 266 -17.90 0.0185
2024-08-12 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,358 252 11.97 325 11.72 0.0241
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,106 31 1.49 290 6.23 0.0229
2024-02-08 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,075 78 3.91 273 21.88 0.0235
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,997 765 62.09 225 93.10 0.0225
2023-08-10 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,232 405 48.97 116 39.76 0.0115
2023-05-11 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 827 -478 -36.63 84 -46.45 0.0087
2023-02-13 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,305 367 39.13 156 55.00 0.0177
2022-11-10 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 938 601 178.34 100 203.03 0.0132
2022-08-09 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 337 -58 -14.68 33 -10.81 0.0044
2022-05-06 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 395 389 6,483.33 37 3,600.00 0.0045
2022-02-01 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 6 -184 -96.84 1 -94.44 0.0001
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 190 131 222.03 18 200.00 0.0025
2021-08-09 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 59 -47 -44.34 6 -40.00 0.0009
2021-05-12 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 106 23 27.71 10 25.00 0.0016
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 83 -215 -72.15 8 -72.41 0.0015
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 298 -439 -59.57 29 -67.78 0.0063
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 737 32 4.54 90 47.54 0.0199
2020-05-15 2020-03-31 13F Neurocrine Biosciences Com 64125C109 705 21 3.07 61 -15.28 0.0102
2020-03-19 2019-12-31 13F/A-1 Neurocrine Biosciences Com 64125C109 684 0 0.00 72 20.00 0.0087
2020-02-03 2019-12-31 13F Neurocrine Biosciences Com 64125C109 684 0 72 243.2974
2019-10-24 2019-09-30 13F Neurocrine Biosciences COM 64125C109 684 0 0.00 60 7.14 0.0092
2019-07-24 2019-06-30 13F Neurocrine Biosciences COM 64125C109 684 30 4.59 56 0.00 0.0089
2019-04-29 2019-03-31 13F Neurocrine Biosciences COM 64125C109 654 647 9,242.86 56 0.0098
2019-01-17 2018-12-31 13F Neurocrine Biosciences COM 64125C109 7 -69 -90.79 0 -100.00
2018-10-29 2018-09-30 13F Neurocrine Biosciences COM 64125C109 76 0 0.00 9 28.57 0.0026
2018-08-08 2018-06-30 13F Neurocrine Biosciences COM 64125C109 76 0 0.00 7 16.67 0.0025
2018-05-10 2018-03-31 13F Neurocrine Biosciences COM 64125C109 76 0 0.00 6 20.00 0.0022
2018-01-31 2017-12-31 13F Neurocrine Biosciences COM 64125C109 76 76 5 0.0020
2017-04-10 2017-03-31 13F Neurocrine Biosciences COM 64125C109 0 -114 -100.00 0 -100.00
2017-01-11 2016-12-31 13F Neurocrine Biosciences COM 64125C109 114 -172 -60.14 4 -71.43 0.0020
2016-10-25 2016-09-30 13F Neurocrine Biosciences COM 64125C109 286 0 0.00 14 7.69 0.0091
2016-07-28 2016-06-30 13F Neurocrine Biosciences COM 64125C109 286 286 0.00 13 0.0089
2016-04-27 2016-03-31 13F Neurocrine Biosciences COM 64125C109 0 -121 -100.00 0 -100.00
2016-01-28 2015-12-31 13F Neurocrine Biosciences COM 64125C109 121 121 6 0.0042
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.